HTRA-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human serine protease HTRA2/Omi (UniProt O43464), expressed in HEK293 cells. Suited for substrate cleavage assays, apoptosis pathway studies, inhibitor profiling, and antibody validation against matched TPB antibody RP-HTRA2.
Expression system
HEK293
Cat. #
REC-HTRA2

In stock

SKU
REC-HTRA2
$498.00

Target Overview

HTRA2 (UniProt O43464), also designated Omi stress-regulated endoprotease and Serine protease 25, is a 458-amino-acid mitochondrial serine protease (EC 3.4.21.108) that localises to the intermembrane space under normal conditions and is released into the cytosol during apoptotic stress. The mature, processed form retains a conserved PDZ domain C-terminal to the chymotrypsin-like catalytic triad, enabling substrate recognition and protease-inhibitor interactions central to apoptosis regulation. This recombinant is produced in HEK293 cells, providing mammalian post-translational processing relevant to studies of the human protein. It is well suited for in vitro serine protease activity assays — including cleavage of non-specific substrates such as β-casein and fluorogenic peptide substrates — as well as biochemical characterisation of its interactions with inhibitor-of-apoptosis (IAP/BIRC) family members. The HEK293-expressed format supports native-like folding, making it applicable to biophysical binding studies (e.g., SPR, ITC) with endogenous binding partners including BIRC6. Researchers selecting this recombinant for antibody validation can pair it directly with the matched Triple Point Biologics anti-HTRA2 antibody (SKU: RP-HTRA2), which is cross-linked on the product page. This pairing provides a defined positive-control standard for Western blot and IHC validation workflows. Additional documented uses include inhibitor IC₅₀ determination in serine protease screens, substrate identification by mass spectrometry following co-incubation, and as a standard in quantitative ELISA development targeting HTRA2 in human cell lysates and tissue samples.

Background

Serine protease HTRA2 (also known as Omi) is a nuclear-encoded, mitochondrially targeted protease that occupies a pivotal position in apoptosis regulation. Under physiological conditions it resides in the mitochondrial intermembrane space; in response to apoptotic stimuli, processed HTRA2 is released into the cytosol, where its N-terminal IAP-binding motif engages BIRC (inhibitor of apoptosis) proteins and its serine protease domain executes downstream proteolytic events. Mechanistically, HTRA2 cleaves BIRC6, relieving its inhibition of caspases 3, 7, and 9, and independently cleaves THAP5, promoting its degradation during apoptosis. These dual caspase-dependent and caspase-independent pro-apoptotic mechanisms make HTRA2 a recurrent subject of cell-death pathway studies. In neurodegeneration research, HTRA2 has attracted sustained attention. Loss-of-function variants in HTRA2 have been associated with parkinsonian phenotypes in genetic studies, and a comprehensive 2026 review (Xu L, Front Pharmacol, 2026) surveys the published evidence positioning HTRA2 as a research target in the context of neurodegenerative diseases, describing how diminished protease activity correlates with accumulation of misfolded mitochondrial substrates and impaired mitophagy-related quality control pathways. The protein has also been investigated in essential tremor genetics (Aghayev A et al., Parkinsonism Relat Disord, 2026), where family-based sequencing implicated neuronal and metabolic pathway genes including HTRA2. Beyond neurodegeneration, HTRA2 has been studied in inflammatory contexts: a 2026 study (Xiao CX et al., Acta Pharmacol Sin, 2026) characterised a small-molecule interaction with HTRA2 as a mechanism mediating effects on the Dectin-1 signalling pathway in a colitis model, illustrating how HTRA2 binding studies in vitro can inform downstream pathway analysis. For researchers working on IAP biology, apoptosis pathway reconstitution, or mitochondrial stress responses, recombinant HTRA2 provides a tractable biochemical tool: the protein is amenable to substrate turnover assays, small-molecule inhibitor profiling, and structural studies of PDZ-domain-mediated interactions. Triple Point Biologics has produced validated proteinase and inhibitor antibody reagents since 1994; the matched anti-HTRA2 antibody (RP-HTRA2), validated for Western blot, is available separately for orthogonal detection of the same target.

Applications

  • Serine protease activity assay against β-casein or fluorogenic peptide substrates (e.g., AMC-conjugated substrates)
  • Inhibitor IC₅₀ determination in small-molecule serine protease screens
  • BIRC6/IAP binding and displacement assays (SPR, co-IP, pull-down)
  • Antibody validation positive control for matched anti-HTRA2 antibody (TPB SKU: RP-HTRA2) by Western blot
  • ELISA calibration standard for quantification of HTRA2 in human cell or tissue lysates
  • Substrate cleavage and identification by co-incubation followed by mass spectrometry (e.g., THAP5, BIRC6 cleavage site mapping)
  • Apoptosis pathway reconstitution assays — caspase activation in cell-free systems
  • Biophysical characterisation of PDZ-domain–peptide interactions (ITC, fluorescence polarisation)

References

  1. Xu L. HtrA2/Omi: potential therapeutic targets for neurodegenerative diseases. Front Pharmacol. 2026. doi:10.3389/fphar.2026.1705666. PMID: 41608412.
  2. Xiao CX et al. 5-OH-TMT mitigates colitis through HTRA2 binding-mediated activation of the Dectin-1 signaling pathway. Acta Pharmacol Sin. 2026. doi:10.1038/s41401-026-01782-0. PMID: 41927825.
  3. Aghayev A et al. Essential tremor: Family-based sequencing suggests involvement of neuronal and metabolic pathways. Parkinsonism Relat Disord. 2026. doi:10.1016/j.parkreldis.2026.108256. PMID: 41762786.
  4. Kurt-Kızıldoğan A et al. Serine Protease HtrA2 from Halophilic Archeon Haloarcula sp. TG1: Heterologous Expression, Characterization and Immobilization. Biomolecules. 2026. doi:10.3390/biom16030424. PMID: 41897361.
  5. Lal JC et al. Gene burden meta-analysis of 748 879 individuals identifies LGI1-ADAM23 protein complex association with epilepsy. Epilepsia. 2026. doi:10.1002/epi.70299. PMID: 42216960.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; mitochondrial intermembrane space (HTRA2)

Frequently Asked Questions

What molecular weight band should I expect for recombinant HTRA2 on SDS-PAGE or Western blot?

Full-length human HTRA2 is 458 amino acids with a predicted unprocessed MW of ~49 kDa. The HEK293-expressed recombinant corresponds to the mature, mitochondria-processed form — the N-terminal mitochondrial targeting sequence (residues ~1–133) is cleaved, yielding the active form at approximately 36 kDa under reducing SDS-PAGE conditions. Glycosylation in the HEK293 system may shift the observed band 1–3 kDa above the theoretical value. Run alongside a pre-stained ladder bracketing 30–50 kDa for reliable sizing.

Which isoform or processing form of HTRA2 is this recombinant — full-length or mature processed?

REC-HTRA2 corresponds to the mature, processed form of HTRA2 (UniProt O43464), beginning after auto-cleavage of the mitochondrial targeting and transmembrane segment. This mirrors the species released into the cytosol during apoptotic stress and retains both the chymotrypsin-like catalytic triad and the C-terminal PDZ domain. It does not include the N-terminal membrane anchor (residues ~1–133), so it is directly relevant to cytosolic apoptosis signalling studies rather than mitochondrial import experiments.

What substrates does HTRA2 cleave and which are recommended for in vitro serine protease activity assays?

HTRA2 (EC 3.4.21.108) exhibits chymotrypsin-like specificity, preferring hydrophobic residues at the P1 position. For in vitro activity assays, β-casein is a commonly used non-specific protein substrate visualised by SDS-PAGE after incubation at 37 °C. For kinetic, fluorimetric readouts, the fluorogenic peptide substrate VDVAD-AMC or Ac-IEPD-AMC can be used (excitation ~360 nm, emission ~460 nm). IAP/BIRC family members — particularly XIAP — serve as physiologically relevant substrates and binding partners for inhibition and competition assays.

What buffer and reaction conditions are recommended for HTRA2 serine protease activity assays?

REC-HTRA2 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and is active in this formulation without further exchange. For fluorogenic substrate assays, dilute into assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT) to a working concentration of 50–200 nM; include DTT to maintain the catalytic cysteine-adjacent residues in reduced form. Avoid Zn²⁺ or Cu²⁺ ions, which inhibit many serine proteases. Reactions are typically run at 37 °C for 30–60 min. Glycerol from the storage buffer (final <1%) does not measurably affect activity at these dilutions.

What starting concentration of recombinant HTRA2 should I use for an IAP binding or inhibition assay?

For pull-down or co-immunoprecipitation assays with IAP/BIRC family proteins, 0.5–1 µg of REC-HTRA2 per reaction is a reasonable starting point. For enzyme inhibition (IC50) determinations against small-molecule or peptide inhibitors, use 50–100 nM enzyme with substrate at or below Km to maintain linear kinetics. Because HTRA2 forms trimers in solution, ensure equimolar comparisons are based on monomer MW (~36 kDa). Titrate inhibitor across at least eight concentrations spanning three orders of magnitude for reliable curve fitting.

Can I use REC-HTRA2 as a Western blot positive control for the matched RP-HTRA2 antibody?

Yes — this is one of the primary design rationales for pairing REC-HTRA2 with RP-HTRA2. The rabbit polyclonal antibody (SKU: RP-HTRA2; details at /anti-htra-2-rabbit-polyclonal-antibody) was validated against the same recombinant protein. Load 20–50 ng of REC-HTRA2 per lane alongside your cell lysates; the ~36 kDa band provides an unambiguous size reference and confirms antibody performance batch-to-batch. This is particularly useful when optimising lysis conditions for mitochondria-enriched fractions, where endogenous HTRA2 signal can be variable.

How much recombinant HTRA2 should I load for Western blot positive control and what dilution of RP-HTRA2 antibody is recommended?

Load 20–50 ng of REC-HTRA2 per lane on a 12% SDS-PAGE gel; this is sufficient to produce a clean ~36 kDa band without overloading. For RP-HTRA2 (SKU: RP-HTRA2), a primary antibody dilution of 1:500–1:2,000 in 5% non-fat milk/TBST is a reliable starting range based on our in-house validation data. Use HRP-conjugated anti-rabbit secondary at 1:5,000–1:10,000. Chemiluminescent exposure of 30–120 seconds is typically sufficient at these protein loads. Refer to the RP-HTRA2 product page for cell-line-specific validation images.

How should I store and handle REC-HTRA2 to preserve serine protease activity long-term?

REC-HTRA2 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and shipped on dry ice. Store at −20 °C in single-use aliquots immediately upon receipt. Avoid repeated freeze-thaw cycles, which degrade enzyme activity; even two additional cycles can reduce activity by >30% for serine proteases of this class. If using only part of an aliquot, dilute the remainder in the supplied buffer supplemented with 0.05% BSA as a carrier, snap-freeze in liquid nitrogen, and store at −80 °C for short-term use within 2 weeks. Do not store at 4 °C beyond 48 hours.

Validation imagery coming soon

Western blot validation figures for REC-HTRA2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →